Server:cloudflare...
The main IP address: 164.109.71.93,Your server United States,Ashburn ISP:MCI Communications Services Inc. d/b/a Verizon Business TLD:uk CountryCode:US
The description :novartis is a global healthcare company based in switzerland that provides solutions to address the evolving needs of patients worldwide....
This report updates in 05-Dec-2018
Created Date: | 26-Aug-1998 |
Changed Date: | 26-Oct-2018 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host savlon.co.uk. Currently, hosted in United States and its service provider is MCI Communications Services Inc. d/b/a Verizon Business .
Latitude: | 39.034080505371 |
Longitude: | -77.488502502441 |
Country: | United States (US) |
City: | Ashburn |
Region: | Virginia |
ISP: | MCI Communications Services Inc. d/b/a Verizon Business |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called cloudflare containing the details of what the browser wants and will accept back from the web server.
Expect-CT: | max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct" |
X-Drupal-Cache: | HIT |
Transfer-Encoding: | chunked |
CF-Cache-Status: | HIT |
Last-Modified: | Wed, 05 Dec 2018 11:18:29 GMT |
X-Frame-Options: | SAMEORIGIN |
X-Request-ID: | bb3fad070f492d818e2e0b5e8b23bc53 |
Content-Language: | en |
Expires: | Thu, 06 Dec 2018 11:20:08 GMT |
Link: | |
Date: | Wed, 05 Dec 2018 11:20:08 GMT |
CF-RAY: | 48461f2eeec5470a-EWR |
X-AH-Environment: | prod |
Set-Cookie: | __cfduid=dd5a0bf88b055a01ebf234d6fd638aa1a1544008808; expires=Thu, 05-Dec-19 11:20:08 GMT; path=/; domain=.novartis.com; HttpOnly |
Server: | cloudflare |
Connection: | keep-alive |
X-Acquia-Application-UUID: | bd001528-a8b3-27d4-29e1-34e36bb6ed42 |
X-Content-Type-Options: | nosniff |
Content-Encoding: | gzip |
X-UA-Compatible: | IE=edge,chrome=1 |
X-Acquia-Application-Trace: | XAe0CwpkJKQAAFd6W7oAAAAM |
Cache-Control: | public, max-age=86400 |
Content-Type: | text/html; charset=utf-8 |
soa: | dns1.idp365.net. hostmaster.idp365.net. 2018082601 28800 1800 604800 3600 |
ns: | dns3.idp365.net. dns2.idp365.net. dns1.idp365.net. |
ipv4: | IP:164.109.71.93 ASN:3707 OWNER:DIGEX3707 - MCI Communications Services, Inc. d/b/a Verizon Business, US Country:US |
mx: | MX preference = 10, mail exchanger = mail.idp365.net. |
navigation content footer global site directory navigate patients & caregivers healthcare professionals media investors search our company our leadership board of directors executive committee of our approach our strategy our culture and values diversity & inclusion our stories portfolio global product portfolio global clinical pipeline media all news media contacts media library stay up-to-date investors event calendar financial data share data & analysis shareholder information corporate responsibility corporate responsibility at expanding access to healthcare ethics, risk and compliance our business oncology pharmaceuticals alcon sandoz our focus disease areas cancer cardio-metabolic immunology & dermatology ophthalmology neuroscience respiratory navigate patients & caregivers healthcare professionals media investors stories discovery from our labs access to healthcare patient perspectives our science stories discovery from our labs access to healthcare patient perspectives research & early development institutes for biomedical research research disease areas postdoc program open source science drug development at global clinical pipeline translational medicine clinical trials join us your career career search careers in research working at corporate responsibility diversity & inclusion our culture and values academic programs students & scholars the step program stories discovery from our labs access to healthcare patient perspectives home at , we are reimagining medicine navigate patients & caregivers healthcare professionals media investors breaking through barriers read the story r&d update highlights industry-leading development pipeline. read more “we progressed our breakthrough medicines pipeline including our leading advanced therapy platforms in cell and gene and continued our strong operational performance.” vas narasimhan, ceo appoints dr. klaus moosmayer as chief ethics risk and compliance officer receives european commission approval of its car-t cell therapy, kymriah® (tisagenlecleucel) to divest the sandoz us dermatology business and generic us oral solids portfolio to aurobindo announces fda and ema filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical spms patients media releases global navigate patients & caregivers healthcare professionals investors media contact us global contacts office locations for investors for media about our company our focus our science our stories our portfolio global product portfolio global clinical pipeline join us career search subscribe to twitter linkedin youtube facebook pinterest instagram site directory © 2018 ag terms of use privacy policy contact us site map this site is intended for a global audience.
https://www.novartis.com/news/media-library
https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-siponimod-first-and-only-drug-shown-meaningfully-delay-disability-progression-typical-spms-patients
https://www.novartis.com/our-focus/healthcare-professionals
https://www.novartis.com/our-science/translational-medicine
https://www.novartis.com/node/121
https://www.novartis.com/our-focus/cancer
https://www.novartis.com/news
https://www.novartis.com/investors/shareholder-information
https://www.novartis.com/investors/share-data-analysis
https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare
https://www.novartis.com/our-focus/healthcare-professionals
https://www.novartis.com/careers/students-scholars
https://www.novartis.com/news/stay-date
https://www.novartis.com/our-company/diversity-inclusion
https://www.novartis.com/terms-use
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain name:
savlon.co.uk
Data validation:
Nominet was not able to match the registrant's name and/or address against a 3rd party source on 26-Oct-2018
Registrar:
Safenames Ltd [Tag = SAFENAMES]
URL: http://www.safenames.net
Relevant dates:
Registered on: 26-Aug-1998
Expiry date: 26-Aug-2019
Last updated: 26-Oct-2018
Registration status:
Registered until expiry date.
Name servers:
dns1.idp365.net
dns2.idp365.net
dns3.idp365.net
WHOIS lookup made at 11:20:10 05-Dec-2018
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REFERRER http://www.nominet.org.uk
REGISTRAR Nominet UK
SERVERS
SERVER co.uk.whois-servers.net
ARGS savlon.co.uk
PORT 43
TYPE domain
DOMAIN
SPONSOR
Safenames Ltd [Tag = SAFENAMES]
URL: http://www.safenames.net
Relevant dates:
CREATED 26-Aug-1998
CHANGED 26-Oct-2018
STATUS
Registered until expiry date.
NSERVER
DNS1.IDP365.NET 217.19.248.20
DNS2.IDP365.NET 31.3.66.150
DNS3.IDP365.NET 207.228.239.80
NAME savlon.co.uk
DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REGISTERED no
The following list shows you to spelling mistakes possible of the internet users for the website searched .